Crystalys Therapeutics’ gout drug, dotinurad, inhibits a known and validated target for treating the chronic disorder, but in a way that could be safer than other drugs. The oral small molecule was discovered and developed in Japan, where it is approved and has a safety record spanning more than 1 million gout patients.
The post Startup Crystalys Therapeutics Emerges With $205M to Fill a Growing Gap in Gout Treatment appeared first on MedCity News.
